Which has higher valuation & earnings, KLRA or CLYM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kailera Therapeutics N/A N/A N/A N/A N/A Climb Bio N/A N/A -$59.85M -$0.78 N/A

Is KLRA or CLYM more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Climb Bio's return on equity. Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A Climb Bio N/A -31.45% -30.39%

Which has higher earnings & valuation, CLYM or VERA?

Climb Bio is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Climb Bio N/A N/A -$59.85M -$0.78 N/A Vera Therapeutics N/A N/A -$299.61M -$5.54 N/A

Is CLYM or VERA more profitable?

Climb Bio's return on equity of -31.45% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Climb Bio N/A -31.45% -30.39% Vera Therapeutics N/A -74.86% -60.18%

Does the media favor CLYM or VERA?

In the previous week, Climb Bio and Climb Bio both had 5 articles in the media. Vera Therapeutics' average media sentiment score of 0.51 beat Climb Bio's score of 0.37 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vera Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, CLYM or TRVI?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Climb Bio N/A N/A -$59.85M -$0.78 N/A Trevi Therapeutics N/A N/A -$42.76M -$0.32 N/A

Is CLYM or TRVI more profitable?

Trevi Therapeutics' return on equity of -24.53% beat Climb Bio's return on equity. Company Net Margins Return on Equity Return on Assets Climb Bio N/A -31.45% -30.39% Trevi Therapeutics N/A -24.53% -23.37%

Does the media favor CLYM or TRVI?

In the previous week, Climb Bio had 2 more articles in the media than Trevi Therapeutics. MarketBeat recorded 5 mentions for Climb Bio and 3 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.63 beat Climb Bio's score of 0.37 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trevi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate NNNN or CLYM?

Climb Bio has a consensus price target of $21.73, suggesting a potential upside of 66.11%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts plainly believe Climb Bio is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Climb Bio 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 3 Strong Buy rating(s) 3.07

Which has higher valuation and earnings, NNNN or CLYM?

Anbio Biotechnology has higher revenue and earnings than Climb Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 241.70 $6.40M N/A N/A Climb Bio N/A N/A -$59.85M -$0.78 N/A

Is NNNN or CLYM more profitable?

Anbio Biotechnology's return on equity of 0.00% beat Climb Bio's return on equity. Company Net Margins Return on Equity Return on Assets Anbio Biotechnology N/A N/A N/A Climb Bio N/A -31.45% -30.39%

Which has preferable earnings & valuation, KOD or CLYM?

Climb Bio is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kodiak Sciences N/A N/A -$229.97M -$4.17 N/A Climb Bio N/A N/A -$59.85M -$0.78 N/A

Is KOD or CLYM more profitable?

Climb Bio's return on equity of -31.45% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Kodiak Sciences N/A -253.85% -81.48% Climb Bio N/A -31.45% -30.39%

Does the media refer more to KOD or CLYM?

In the previous week, Climb Bio had 3 more articles in the media than Kodiak Sciences. MarketBeat recorded 5 mentions for Climb Bio and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 1.38 beat Climb Bio's score of 0.37 indicating that Kodiak Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Climb Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Climb Bio (CLYM) Competitors

$13.08 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$13.12 +0.04 (+0.31%)

As of 06/26/2026 06:47 PM Eastern

Compare

CLYM vs. KLRA, VERA, TRVI, NNNN, and KOD

Should you buy Climb Bio stock or one of its competitors? MarketBeat compares Climb Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Climb Bio include Kailera Therapeutics (KLRA), Vera Therapeutics (VERA), Trevi Therapeutics (TRVI), Anbio Biotechnology (NNNN), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry.

How does Climb Bio compare to Kailera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Climb Bio (NASDAQ:CLYM) are both pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

69.8% of Climb Bio shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Kailera Therapeutics currently has a consensus target price of $42.75, indicating a potential upside of 105.23%. Climb Bio has a consensus target price of $21.73, indicating a potential upside of 66.11%. Given Kailera Therapeutics' higher probable upside, analysts clearly believe Kailera Therapeutics is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

Kailera Therapeutics' return on equity of 0.00% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Climb Bio	N/A	-31.45%	-30.39%

In the previous week, Climb Bio had 4 more articles in the media than Kailera Therapeutics. MarketBeat recorded 5 mentions for Climb Bio and 1 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 1.44 beat Climb Bio's score of 0.37 indicating that Kailera Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Kailera Therapeutics	Positive
Climb Bio	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

Summary

Climb Bio beats Kailera Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Climb Bio compare to Vera Therapeutics?

Climb Bio (NASDAQ:CLYM) and Vera Therapeutics (NASDAQ:VERA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

Climb Bio's return on equity of -31.45% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.45%	-30.39%
Vera Therapeutics	N/A	-74.86%	-60.18%

Climb Bio is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by company insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Climb Bio and Climb Bio both had 5 articles in the media. Vera Therapeutics' average media sentiment score of 0.51 beat Climb Bio's score of 0.37 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vera Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Climb Bio presently has a consensus price target of $21.73, indicating a potential upside of 66.11%. Vera Therapeutics has a consensus price target of $78.00, indicating a potential upside of 83.70%. Given Vera Therapeutics' higher possible upside, analysts clearly believe Vera Therapeutics is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Climb Bio has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

Summary

Climb Bio and Vera Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Climb Bio compare to Trevi Therapeutics?

Climb Bio (NASDAQ:CLYM) and Trevi Therapeutics (NASDAQ:TRVI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

Climb Bio has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market.

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A

Trevi Therapeutics' return on equity of -24.53% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.45%	-30.39%
Trevi Therapeutics	N/A	-24.53%	-23.37%

Climb Bio presently has a consensus price target of $21.73, indicating a potential upside of 66.11%. Trevi Therapeutics has a consensus price target of $22.90, indicating a potential upside of 26.17%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts clearly believe Climb Bio is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Climb Bio had 2 more articles in the media than Trevi Therapeutics. MarketBeat recorded 5 mentions for Climb Bio and 3 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.63 beat Climb Bio's score of 0.37 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Trevi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

69.8% of Climb Bio shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 2.6% of Climb Bio shares are held by company insiders. Comparatively, 18.3% of Trevi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Trevi Therapeutics beats Climb Bio on 8 of the 14 factors compared between the two stocks.

How does Climb Bio compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Climb Bio (NASDAQ:CLYM) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Anbio Biotechnology has higher revenue and earnings than Climb Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	241.70	$6.40M	N/A	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

Anbio Biotechnology's return on equity of 0.00% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Climb Bio	N/A	-31.45%	-30.39%

Anbio Biotechnology has a beta of 4.4, suggesting that its stock price is 340% more volatile than the broader market. Comparatively, Climb Bio has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

Climb Bio has a consensus price target of $21.73, suggesting a potential upside of 66.11%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts plainly believe Climb Bio is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

69.8% of Climb Bio shares are held by institutional investors. 2.6% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Climb Bio had 4 more articles in the media than Anbio Biotechnology. MarketBeat recorded 5 mentions for Climb Bio and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.87 beat Climb Bio's score of 0.37 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Anbio Biotechnology	Very Positive
Climb Bio	Neutral

Summary

Climb Bio beats Anbio Biotechnology on 7 of the 13 factors compared between the two stocks.

How does Climb Bio compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and Climb Bio (NASDAQ:CLYM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

89.1% of Kodiak Sciences shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 45.9% of Kodiak Sciences shares are held by company insiders. Comparatively, 2.6% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Climb Bio had 3 more articles in the media than Kodiak Sciences. MarketBeat recorded 5 mentions for Climb Bio and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 1.38 beat Climb Bio's score of 0.37 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Climb Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Climb Bio is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

Climb Bio's return on equity of -31.45% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-253.85%	-81.48%
Climb Bio	N/A	-31.45%	-30.39%

Kodiak Sciences currently has a consensus price target of $42.14, suggesting a potential upside of 17.26%. Climb Bio has a consensus price target of $21.73, suggesting a potential upside of 66.11%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts clearly believe Climb Bio is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

Kodiak Sciences has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market. Comparatively, Climb Bio has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

Summary

Climb Bio beats Kodiak Sciences on 9 of the 14 factors compared between the two stocks.

Get Climb Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLYM vs. The Competition

Export

Metric	Climb Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$748.96M	$3.63B	$7.03B	$12.19B
Dividend Yield	N/A	2.21%	2.66%	6.11%
P/E Ratio	-16.77	21.56	26.13	24.16
Price / Sales	N/A	334.26	555.66	102.83
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	3.89	8.31	10.78	6.38
Net Income	-$59.85M	$23.92M	$3.58B	$337.00M
7 Day Performance	7.39%	1.93%	1.97%	-0.20%
1 Month Performance	19.34%	-0.41%	-0.24%	-1.40%
1 Year Performance	1,008.47%	65.22%	34.39%	27.76%

Climb Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLYM Climb Bio	2.8624 of 5 stars	$13.08 flat	$21.73 +66.1%	+1,008.5%	$748.96M	N/A	N/A	9	Gap Down High Trading Volume
KLRA Kailera Therapeutics	4.9603 of 5 stars	$19.94 +0.2%	$42.75 +114.4%	N/A	$2.58B	N/A	N/A	145	Positive News High Trading Volume
VERA Vera Therapeutics	3.3232 of 5 stars	$35.09 flat	$78.00 +122.3%	+87.5%	$2.52B	N/A	N/A	40	Gap Down
TRVI Trevi Therapeutics	2.615 of 5 stars	$17.21 flat	$22.90 +33.1%	+223.0%	$2.44B	N/A	N/A	20	High Trading Volume
NNNN Anbio Biotechnology	0.8968 of 5 stars	$16.64 flat	N/A	N/A	$2.39B	$8.65M	N/A	27	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLYM) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Climb Bio (CLYM) Competitors

CLYM vs. KLRA, VERA, TRVI, NNNN, and KOD

How does Climb Bio compare to Kailera Therapeutics?

Summary

How does Climb Bio compare to Vera Therapeutics?

Summary

How does Climb Bio compare to Trevi Therapeutics?

Summary

How does Climb Bio compare to Anbio Biotechnology?

Summary

How does Climb Bio compare to Kodiak Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM vs. The Competition

Climb Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Climb Bio (CLYM) Competitors

CLYM vs. KLRA, VERA, TRVI, NNNN, and KOD

How does Climb Bio compare to Kailera Therapeutics?

Do insiders and institutionals believe in KLRA or CLYM?

Do analysts rate KLRA or CLYM?

Is KLRA or CLYM more profitable?

Does the media refer more to KLRA or CLYM?

Which has higher valuation & earnings, KLRA or CLYM?

Summary

How does Climb Bio compare to Vera Therapeutics?

Is CLYM or VERA more profitable?

Which has higher earnings & valuation, CLYM or VERA?

Do institutionals & insiders hold more shares of CLYM or VERA?

Does the media favor CLYM or VERA?

Do analysts prefer CLYM or VERA?

Which has more volatility and risk, CLYM or VERA?

Summary

How does Climb Bio compare to Trevi Therapeutics?

Which has more risk and volatility, CLYM or TRVI?

Which has higher valuation and earnings, CLYM or TRVI?

Is CLYM or TRVI more profitable?

Do analysts recommend CLYM or TRVI?

Does the media favor CLYM or TRVI?

Do institutionals and insiders hold more shares of CLYM or TRVI?

Summary

How does Climb Bio compare to Anbio Biotechnology?

Which has higher valuation and earnings, NNNN or CLYM?

Is NNNN or CLYM more profitable?

Which has more volatility and risk, NNNN or CLYM?

Do analysts rate NNNN or CLYM?

Do insiders & institutionals hold more shares of NNNN or CLYM?

Does the media refer more to NNNN or CLYM?

Summary

How does Climb Bio compare to Kodiak Sciences?

Do institutionals & insiders believe in KOD or CLYM?

Does the media refer more to KOD or CLYM?

Which has preferable earnings & valuation, KOD or CLYM?

Is KOD or CLYM more profitable?

Do analysts prefer KOD or CLYM?

Which has more volatility and risk, KOD or CLYM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM vs. The Competition

Climb Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools